Telix Pharmaceuticals (TLX) Accounts Payables (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Accounts Payables data on file, last reported at $150.3 million in Q4 2025.

• Accounts Payables for Q4 2025 came in at $150.3 million, up 64.3% year-over-year; the trailing twelve-month figure through Dec 2025 was $150.3 million (up 64.3% YoY), and the FY2025 annual result was $150.3 million, up 73.23% from the prior year.
• Accounts Payables rose to $150.3 million in Q4 2025 per TLX's latest filing, from $91.5 million in the prior quarter.
• Over five years, Accounts Payables peaked at $150.3 million in Q4 2025 and troughed at $21.4 million in Q4 2023.
• A 3-year average of $87.7 million and a median of $91.5 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables jumped 328.07% in 2024, then surged 64.3% in 2025.
• A 3-year view of Accounts Payables shows it stood at $21.4 million in 2023, then surged by 328.07% to $91.5 million in 2024, then surged by 64.3% to $150.3 million in 2025.
• Business Quant data shows TLX's Accounts Payables at $150.3 million in Q4 2025, $91.5 million in Q4 2024, and $21.4 million in Q4 2023.